Glenmark Pharmaceuticals Launches Generic Inlyta Tablets in US
Glenmark's US arm launched Axitinib Tablets, 1 mg and 5 mg, an authorized generic of Pfizer's INLYTA.
Key Takeaways
- Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets, 1 mg and 5 mg, on November 16, 2026.
- The product is an authorized generic of Pfizer's INLYTA, used for advanced renal cell carcinoma.
- IQVIA data cited by Glenmark puts US INLYTA sales at about $538.4 million for the 12 months ending September 2026.
- Glenmark ships its US medicines from its Allentown hub to 321 locations in 43 states.
- Glenmark has not disclosed expected revenue from the launch.
Table of Contents 5 sections
Glenmark Pharmaceuticals said on November 16, 2026, that its US subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Axitinib Tablets in 1 mg and 5 mg strengths in the United States. The company said the product is an authorized generic version of INLYTA (axitinib) tablets, a registered trademark of Pfizer Inc.
INLYTA is used to treat advanced renal cell carcinoma, a type of kidney cancer. According to IQVIA sales data for the 12 months ending September 2026, as cited by Glenmark, US annual sales of INLYTA tablets were about $538.4 million. That figure is the US sales of the reference brand, not Glenmark's own sales from the new product.
Glenmark's axitinib launch at a glance
| Detail | Value |
|---|---|
| Company | Glenmark Pharmaceuticals Inc., USA, the US subsidiary of Glenmark Pharmaceuticals Ltd. |
| Product | Axitinib Tablets, 1 mg and 5 mg |
| Type | Authorized generic of INLYTA (axitinib) tablets |
| Brand owner | INLYTA is a registered trademark of Pfizer Inc. |
| Used for | Advanced renal cell carcinoma, a type of kidney cancer |
| Market | United States |
| US sales of INLYTA | About $538.4 million in the 12 months ending September 2026, per IQVIA data cited by Glenmark |
| Announced | November 16, 2026 |
How axitinib fits Glenmark's US business
Glenmark Pharmaceuticals is a Mumbai-based pharmaceutical company listed on the BSE and NSE. It sells branded, generic, innovative and consumer health products in more than 80 countries, with a focus on respiratory, dermatology and oncology.
In the US, Glenmark ships prescription and over-the-counter medicines from a distribution center in Allentown, Pennsylvania, which it inaugurated in October 2026. The company said the roughly 160,000-square-foot facility is its sole US distribution hub and serves 321 locations in 43 states with 45 employees. For the quarter ended September 30, 2026, Glenmark reported consolidated revenue of about Rs 4,247 crore and adjusted profit after tax of about Rs 485 crore.
| When | What happened |
|---|---|
| October 2026 | Glenmark inaugurated its Allentown, Pennsylvania distribution center, its sole US distribution hub |
| November 5, 2026 | Glenmark reported Q2 FY27 consolidated revenue of about Rs 4,247 crore |
| November 16, 2026 | Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets, 1 mg and 5 mg |
Marc Kikuchi on access to affordable medicines
"The launch of Axitinib Tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States."
Kikuchi also said that by adding the product to its portfolio, Glenmark continues to strengthen its focus on the evolving needs of patients and healthcare providers. The company has not disclosed how much revenue it expects from the launch.
Where Glenmark's US oncology range stands after the launch
With this launch, Glenmark Pharmaceuticals Inc., USA now sells Axitinib Tablets in 1 mg and 5 mg strengths as an authorized generic of Pfizer's INLYTA. The reference brand recorded about $538.4 million in US sales in the 12 months ending September 2026, according to IQVIA data cited by the company. Glenmark ships its US medicines from its Allentown hub to 321 locations in 43 states.
More news
Frequently Asked Questions
What did Glenmark Pharmaceuticals launch in the US?
What is Glenmark's axitinib product a generic of?
What is INLYTA used to treat?
How big is the US market for INLYTA?
How many strengths of axitinib did Glenmark launch?
How much revenue does Glenmark expect from axitinib?
Who announced the axitinib launch for Glenmark?
What did Marc Kikuchi say about the launch?
Which Glenmark company made the launch?
How does Glenmark distribute medicines in the US?
What is Glenmark Pharmaceuticals?
What was Glenmark's revenue in Q2 FY27?
More in Business
PTC Industries H1 Profit Rises About 168% to Rs 62.47 Crore
PTC Industries posted a Rs 62.47 crore consolidated profit for H1 FY27, up about 168% from a year ago.
Vikram Solar Q2 Profit Falls About 95% to Rs 5.93 Crore
Vikram Solar's Q2 FY27 profit fell about 95% to Rs 5.93 crore as revenue slipped 2.9% to Rs 1,077 crore.
Kalpataru Projects Wins About Rs 2,610 Crore Power Order
Kalpataru Projects has won an EPC order worth about Rs 2,610 crore for power lines and substations.
